Gall Matthew

Gall Matthew is listed in filings as Chief Financial Officer at Tango Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 5, 2026, including purchase activity. Recent filings connect the profile to Tango Therapeutics, Inc. (TNGX), Kalaris Therapeutics Inc (KLRS), and iTeos Therapeutics, Inc. (ITOS). The current snapshot covers public activity from Nov 19, 2024 to May 5, 2026. Reported amounts are shown as $5.0M to $1.2M. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.